Astrazeneca's covid antibody drug heads into advanced trials
Astrazeneca started late-stage trials for an antibody medicine against Covid-19 with a large investment from the U.S., after President Donald Trump credited a similar therapy with aiding his recovery.
By Marthe Fourcade and Suzi Ring, Bloomberg
Two trials for more than 6,000 people are starting in the next few weeks looking at prevention, with plans for a further 4,000 adults to test the antibody medicine as a treatment, Astrazeneca said in a statement. The drug will be assessed for its ability to avoid infections for as much as a year in some people and as a pre-emptive medicine once patients have been exposed to the virus in others.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
